D. Skee

发表

Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants

J. Murphy, J. Snoeys, R. de Vries, 2015, Pharmacology research & perspectives.

Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants

E. Wajs, K. Usiskin, J. Murphy, 2015, Clinical pharmacology in drug development.

Absorption, Metabolism, and Excretion of Oral 14C Radiolabeled Ibrutinib: An Open-Label, Phase I, Single-Dose Study in Healthy Men

L. Leclercq, J. Murphy, J. de Jong, 2015, Drug Metabolism and Disposition.

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin

S. Schwartz, L. Morrow, J. Murphy, 2012, Diabetes, obesity & metabolism.

Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma

D. Esseltine, K. Venkatakrishnan, P. Moreau, 2012, Clinical Pharmacokinetics.

Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites.

G. Anderson, J. Natarajan, F. Wong, 2002, British journal of clinical pharmacology.

Multiple-dose pharmacokinetics of a contraceptive patch in healthy women participants.

J. Natarajan, F. Wong, K. Lasseter, 2001, Contraception.

Pharmacokinetic overview of Ortho Evra/Evra.

J. Natarajan, F. Wong, D. Skee, 2002, Fertility and sterility.

UPLC-MS/MS assay for the simultaneous determination of ethinyl estradiol, norgestimate and 17-Desacetyl norgestimate at low pg/mL in human plasma.

Naidong Weng, D. Skee, T. Verhaeghe, 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia

J. Byrd, S. O'brien, J. Murphy, 2015, Cancer Chemotherapy and Pharmacology.

Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults.

Juthamas Sukbuntherng, Jan Snoeys, L. D. De Zwart, 2016, British journal of clinical pharmacology.

Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment*

William Smith, T. Marbury, E. Lawitz, 2017, Leukemia & lymphoma.

Pharmacokinetic model and simulations of dose conversion from immediate- to extended-release tramadol*

D. Skee, G. Vorsanger, B. Moskovitz, 2007, Current medical research and opinion.

Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkin’s Lymphoma

J. Walewski, O. Shpilberg, S. Rule, 2011, Clinical pharmacokinetics.

Soft-Tissue Penetration of Ceftobiprole in Healthy Volunteers Determined by In Vivo Microdialysis

M. Grant, H. Derendorf, C. Seubert, 2009, Antimicrobial Agents and Chemotherapy.

P779 Pharmacokinetics of ceftobiprole following single and multiple intravenous infusions administered to healthy subjects

G. Noel, D. Skee, D. Balis, 2007 .

A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma

P. Moreau, X. Leleu, T. Robak, 2010 .

Pharmacokinetics and Pharmacodynamics of a Transdermal Contraceptive Patch and an Oral Contraceptive

L. Janssens, N. Vaccaro, D. Skee, 2007, Journal of clinical pharmacology.

Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL).

J. Friedberg, I. Flinn, Y. Oki, 2013 .

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Characteristics

D. Esseltine, K. Venkatakrishnan, P. Moreau, 2011 .